Dr. Reddy wrongly remembered the seizure injection at consumer level in the US

Drug maker Dr. Reddy’s laboratories are remembering a batch of 0.75% sodium chloride injection, 1,000 mg/100 ml (10 mg/ml) in the US in the US in the US in the US in a single-khurak infusion bag in the laboratories, 1,000 mg/100 ml (10 mg/ml) in single-khurak infusion bags.

The infusion bag is incorrectly labeled as leverecatum in 0.82% sodium chloride injection 500 mg/100 mL single-dose bag, while aluminum overdrape packaging correctly is recognized as a 0.75% sodium chloride injection 1,000 mg/100 ml, the company recognizes the form of a levera Said.

Both have been indicated for auxiliary therapy in adults with partial start seizures; Myoclonic seizures in patients with adolescent myoclonic epilepsy; And primary generalized tonic-clonic seizures. Missalabeld product administered patients will be likely to experience adverse events.

Since the infusion bag is labelled as 500 mg/100 ml but contains 1,000 mg/100 ml dose, the patient could receive double the dose of intravenous Levetiracetam Than INDED, which count account to IMDITE and Serous Side effects, include hypersensitivity reactions, liver injury, haematological toxicity, somnolence, fatigue, dizziness, coordination, coordination, courses, agitation, aggregation, aggregation, aggregation Consciousness, respiratory depression and coma.

The condition of the condition of epilepsy will be at greater risk for serious adverse events to the patients receiving high doses of levetrasatum by rapid intravenous infusion. Dr. Reddy said no reports of adverse incidents related to recall have been received. The respective batch was distributed to wholesalers between November 4, 2024 in the US.

This memory is being executed with knowledge of the US Food and Drug Administration (US FDA), the company said.